Dr. Williamson was an Associate Professor in the Department of Immunology at The Scripps Research Institute (TSRI), before joining Calmune as President and CEO. He has been involved in the isolation and development of neutralizing human antibodies against HSV, RSV, EBV, and many other human pathogenic viruses, as well as the development of the first monoclonal antibodies against prion proteins, the agents responsible for Bovine Spongiform Encephalitis (BSE or “Mad Cow Disease”). These antibodies were the basis of a diagnostic test for BSE commercialized by Prion Solutions, a company developed and acquired by Chiron. Dr. Williamson received his B.Sc. in Biochemistry and Microbiology from the University Sheffield, where he also earned his Ph.D. in Molecular Immunology and Antibody Engineering in 1993.

Dr. Burton is currently a Professor in the Departments of Immunology and Molecular Biology at TSRI and is a leading expert in the structure and function of antibody molecules. His research currently focuses upon the understanding the antibody response to infectious pathogens. Dr. Burton is known for having produced the first human antibodies selected from phage libraries and the first neutralizing human antibodies against HIV, RSV, Ebola virus and hepatitis C virus. Dr. Burton has founded two biotechnology companies: Prolifaron and, together with Dr. Williamson, Prion Solutions. Dr. Burton received his degree in Chemistry at Oxford University in 1974 and his PhD in Nuclear Magnetic Resonance from the University of Lund in Sweden in 1978. He has authored over 250 original articles.

Dr. Sanna is an Associate Professor in the Department of Molecular and Integrative Neurosciences, at TSRI. He has authored over 65 original articles and has made several seminal contributions in the areas of neurobiology and immunobiology of neural diseases and has contributed to the isolation and characterization of human recombinant antibodies against HSV, CMV and other pathogens. Dr. Sanna received his M.D. in 1986, and his post-graduate specialty in Clinical Pharmacology in 1990, from the A. Gemelli Medical School in Rome, Italy.